Infectologia

Estudo do CDC | Vacina contra COVID-19 está associada com proteção 5 vezes maior que a “imunidade natural”.

1 Nov, 2021 | 10:59h

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Comentários:

COVID-19 vaccine gives 5 times the protection of ‘natural immunity,’ data show – CIDRAP

COVID shots more protective than past infection, study shows – Associated Press

 

Comentário no Twitter

⚠️BREAKING—REINFECTION & NATURAL IMMUNITY—new CDC study in hospitalized adults finds: unvaccinated people with prior #COVID19 infection recently were **5 times more likely** to be reinfected / get breakthrough versus people recently fully vaccinated! 🧵 https://t.co/VGmWPmm5lE pic.twitter.com/mlt5fJ3643

— Eric Feigl-Ding (@DrEricDing) October 29, 2021

 

---

Opinião | A vacina da Moderna é realmente melhor que a da Pfizer – ou é somente uma dose maior?

1 Nov, 2021 | 10:58h

Is Moderna Really Better Than Pfizer—Or Is It Just a Higher Dose? – The Atlantic

Conteúdo relacionado: CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

 

Comentário no Twitter

Nice piece @theatlantic explores question of: Does Moderna give better protection than Pfizer, which gives better protection than J&J (the data would say yes to both)? And – if so – is it simply a matter of the relative doses? https://t.co/Bqav2pNNi7

— Bob Wachter (@Bob_Wachter) October 30, 2021

 

---

Revisão | Como abordar um paciente com bacteriemia por Staphylococcus aureus resistente à meticilina.

1 Nov, 2021 | 10:50h

How I manage a patient with MRSA bacteraemia – Clinical Microbiology and Infection

---

A efetividade da vacina da AstraZeneca em idosos durante a circulação da variante gama do SARS-CoV-2 em São Paulo foi de 77,9% contra Covid-19 sintomática, 87,6% contra internação e 93,6% contra morte.

29 Out, 2021 | 14:59h

Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo – Nature Medicine

 

Comentário no Twitter (fio – clique para saber mais)

Effectiveness of Oxford-AstraZeneca COVID-19 vaccine by dose in over 60s in São Paulo state, published today in @NatureComms with @juliocroda @otavio_ranzani @datcummings as part of the VEBRA COVID-19 group 1/8https://t.co/zIbPb45nEJ

— Matt Hitchings (@MHitchingsEpi) October 28, 2021

 

---

Atualização sobre as sequelas pós-agudas da infecção por SARS-CoV-2: cuidados clínicos aos portadores de “long Covid”.

29 Out, 2021 | 14:57h

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’ – Cleveland Clinic Journal of Medicine

Conteúdos relacionados:

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)

---

Subnotificação de mortes limita a compreensão sobre o verdadeiro impacto da Covid-19.

29 Out, 2021 | 14:54h

Under-reporting of deaths limits our understanding of true burden of covid-19 – The BMJ

Conteúdos relacionados:

Study shows COVID-19 has caused the biggest decrease in life expectancy since World War II.

Just how do deaths due to COVID-19 stack up?

Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset.

Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.

Report: Three new estimates of India’s all-cause excess mortality during the COVID-19 Pandemic – pandemic death toll estimated to be between 3.4 million and 4.9 million excess deaths.

COVID-19 has caused 6.9 million deaths globally, more than double what official reports show

 

Comentário no Twitter

Mortality data have been essential in understanding the spread of covid-19 and navigating the trade-offs that underlie political decision making, yet under-reporting in official death records has greatly obscured this understanding.

What should be done?https://t.co/pI8aVpa3NR

— The BMJ (@bmj_latest) October 14, 2021

 

---

Vacinas de mRNA induzem memória imunológica durável contra SARS-CoV-2 e variantes de preocupação.

29 Out, 2021 | 14:53h

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern – Science

 

Comentário do autor no Twitter (fio – clique para saber mais)

Antibodies come and go, but memory cells are forever (maybe not forever, but at least 6 months). Our latest in @ScienceMagazine: https://t.co/YHHBMrMsTA

How long does immune memory last after #mRNA vax? Is it effective vs. variants? What about “boosted” responses?

Full 🧵⬇️… pic.twitter.com/oZ5BxLuVdw

— Rishi Goel (@rishirajgoel) October 14, 2021

 

---

Nove palavras pandêmicas que poucos acertam como utilizar.

29 Out, 2021 | 14:50h

Nine Pandemic Words That Almost No One Gets Right – The Atlantic

---

Estudo randomizado | Tratamento precoce com fluvoxamina reduziu o risco de cuidado de emergência e internação entre pacientes com COVID-19.

28 Out, 2021 | 16:22h

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial – The Lancet Global Health

Comentários:

Expert reaction to study looking at fluvoxamine as a COVID-19 treatment in high-risk outpatients with early-diagnosed COVID-19 – Science Media Centre

The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM

The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews

Conteúdos relacionados:

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Comentário no Twitter

NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY

— The Lancet (@TheLancet) October 27, 2021

 

---

Estudo randomizado | Tratamento precoce da Covid-19 com sotrovimabe (anticorpo neutralizante do SARS-CoV-2) está associado a risco reduzido de internação.

28 Out, 2021 | 16:18h

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab – New England Journal of Medicine

 

Comentário no Twitter

In this phase 3 trial, sotrovimab or placebo was administered to outpatients within 5 days after the onset of #COVID19 symptoms. Patients receiving sotrovimab had a lower incidence of hospitalization for any reason. #IDTwitter https://t.co/4VcgoK3xac pic.twitter.com/W82v3jNRmB

— NEJM (@NEJM) October 27, 2021

 

---